Tourmaline Bio, Inc.
TRML · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $514 | $124 | $207 | $1,663 |
| - Cash | $31 | $141 | $8 | $19 |
| + Debt | $0 | $0 | $1 | $0 |
| Enterprise Value | $484 | -$16 | $200 | $1,644 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$0 | -$0 | -$0 | -$1 |
| % Margin | – | – | – | – |
| EBITDA | -$90 | -$42 | -$20 | -$47 |
| % Margin | – | – | – | – |
| Net Income | -$73 | -$42 | -$20 | -$0 |
| % Margin | – | – | – | – |
| EPS Diluted | -2.89 | -8.87 | -0.97 | -0 |
| % Growth | 67.4% | -814.4% | -969,900% | – |
| Operating Cash Flow | -$77 | -$28 | -$6 | -$40 |
| Capital Expenditures | -$0 | -$0 | -$5 | -$2 |
| Free Cash Flow | -$77 | -$28 | -$12 | -$42 |